Absci Corporation (NASDAQ:ABSI - Get Free Report) shares traded up 14.6% during mid-day trading on Wednesday. The stock traded as high as $8.25 and last traded at $8.6890. 690,408 shares traded hands during trading, a decline of 84% from the average daily volume of 4,321,190 shares. The stock had previously closed at $7.58.
Analysts Set New Price Targets
ABSI has been the subject of a number of research analyst reports. KeyCorp increased their target price on Absci from $16.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, October 16th. Wall Street Zen raised shares of Absci from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Needham & Company LLC increased their price target on Absci from $11.00 to $15.00 and gave the company a "buy" rating in a report on Thursday, November 12th. Jefferies Financial Group initiated coverage on shares of Absci in a report on Thursday, October 29th. They issued a "buy" rating and a $14.00 price objective for the company. Finally, Guggenheim decreased their target price on shares of Absci from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Monday. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Absci presently has a consensus rating of "Moderate Buy" and an average target price of $14.90.
View Our Latest Analysis on Absci
Absci Trading Up 9.1%
The company has a fifty day simple moving average of $9.60 and a two-hundred day simple moving average of $6.85. The company has a market cap of $1.43 billion, a PE ratio of -10.37 and a beta of 2.22.
Absci (NASDAQ:ABSI - Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.66 million. Absci had a negative return on equity of 61.60% and a negative net margin of 8,451.31%. On average, research analysts anticipate that Absci Corporation will post -0.76 EPS for the current fiscal year.
Hedge Funds Weigh In On Absci
A number of large investors have recently made changes to their positions in ABSI. BlackRock Inc. acquired a new position in shares of Absci during the second quarter worth approximately $141,112,000. Marshall Wace LLP raised its stake in Absci by 287.3% during the 3rd quarter. Marshall Wace LLP now owns 1,945,901 shares of the company's stock valued at $20,957,000 after acquiring an additional 1,443,494 shares in the last quarter. Integral Health Asset Management LLC raised its stake in Absci by 62.5% during the 3rd quarter. Integral Health Asset Management LLC now owns 1,300,000 shares of the company's stock valued at $14,001,000 after acquiring an additional 500,000 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new position in Absci during the 2nd quarter worth $10,366,000. Finally, Bank of America Corp DE bought a new position in shares of Absci in the second quarter worth $6,560,000. Hedge funds and other institutional investors own 52.05% of the company's stock.
Absci Company Profile
(
Get Free Report)
Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Absci, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.
While Absci currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.